With 40 years of pioneering ADHD treatments, Laboratorios Rubió has always been at the forefront of improving the quality of life for patients with ADHD. Now, as artificial intelligence (AI) transforms healthcare, we are part of this groundbreaking shift with our collaboration with Sincrolab.
Sincrolab is an innovative digital platform, using AI to treat cognitive diseases through gamification. This AI-driven technology stimulates the brain’s cognitive processes in both children and adults with ADHD, providing a unique and effective approach to treatment.
Sincrolab’s approach is scientifically validated, with clinical trials published in high-impact scientific journals, earning the support of the scientific community. In the first Spanish placebo-controlled trial of a digital therapy, Sincrolab proved significantly more effective than a placebo, helping 73% of patients with ADHD achieve cognitive improvements in inhibitory control.
To learn more about Sincrolab, click here: Sincrolab.
The innovative treatment offered by Sincrolab is a training platform aimed at the recovery and development of cognitive abilities. Using a personalized stimulation system, patients perform tasks designed by specialist neuroscientists through a mobile application. These interventions aim to reorganize the brain connectivity of patients suffering from neurocognitive disorders.
Our association with Sincrolab shows our firm commitment to Digital Therapeutics and the future of medicine and neurocognitive rehabilitation treatments. With our patient-focused strategy, we strive to offer products and services that enhance the quality of life for each individual.
We are confident that our collaboration with Sincrolab will bring considerable success to both companies and, more importantly, to all our patients.
At Laboratorios Rubió, we are committed to our patients and dedicated to investing in innovation and the development of new products that enhance their health. As part of our mission, we have started 2022 with exciting developments, such as entering the OTC market through the acquisition of Fisiopharma and our investment in Sincrolab’s groundbreaking ADHD treatment.
With over 50 years of experience, we understand what health professionals need to provide quality healthcare to their patients. This collaboration with Sincrolab represents a significant step forward in our continued efforts to develop increasingly accurate treatments, using cutting-edge technology.
